Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches
| Autor: | Oana Alexandru, Cristina Horescu, Ani-Simona Sevastre, Catalina Cioc, Carina Baloi, Alexandru Oprita, Anica Dricu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Contemporary Oncology, Vol 24, Iss 1, Pp 55-66 (2020) |
| Druh dokumentu: | article |
| ISSN: | 1428-2526 1897-4309 |
| DOI: | 10.5114/wo.2020.94726 |
| Popis: | From all central nervous system tumors, gliomas are the most common. Nowadays, researchers are looking for more efficient treatments for these tumors, as well as ways for early diagnosis. Receptor tyrosine kinases (RTKs) are major targets for oncology and the development of small-molecule RTK inhibitors has been proven successful in cancer treatment. Mutations or aberrant activation of the RTKs and their intracellular signaling pathways are linked to several malignant diseases, including glioblastoma. The progress in the understanding of malignant glioma evolution has led to RTK targeted therapies with high capacity to improve the therapeutic response while reducing toxicity. In this review, we present the most important RTKs (i.e. EGFR, IGFR, PDGFR and VEGFR) currently used for developing cancer therapeutics together with the potential of RTK-related drugs in glioblastoma treatment. Also, we focus on some therapeutic agents that are currently at different stages of research or even in clinical phases and proved to be suitable as re-purposing candidates for glioblastoma treatment. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|